Celularity- Warrants (16/07/2026) EBIT

As of the most recent data (December 2025), CELUW shows a EBIT of $-85M. That compares with $-67M in the prior-year period — down 27.6% year over year. That is below the Healthcare sector average of $22B. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, CELUW's EBIT is now $-85M (was $-67M) — a 27.6% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Celularity- Warrants (16/07/2026) is outperforming or lagging.

The Healthcare sector average EBIT is about $22B. Celularity- Warrants (16/07/2026) is at $-85M, which is lower that average. That is roughly 100.4% below the sector mean. Use the comparison chart on this page to see how CELUW stacks up against individual peers as well.

Tracking CELUW's ebit over time shows whether Celularity- Warrants (16/07/2026) is scaling, shrinking, or reshaping that part of the business. The current reading is $-85M That compares with $-67M in the prior-year period — down 27.6% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has Celularity- Warrants (16/07/2026)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $-85M) with ownership activity and broader fundamentals.